Cannabis Policy & Regulatory Digest: 3 Official Updates (September 2026)
{ "@context": "https://schema.org", "@type": [ "CollectionPage", "NewsArticle" ], "headline": "Cannabis Policy & Regulatory Digest: 3 Official Updates (September 2026)",…
DEA Synthetic Opioids Schedule I Placement Updates 2026
This update covers DEA synthetic opioids schedule I placement actions affecting clinical and regulatory landscapes in 2026. These changes influence substance classification and patient care considerations. Stay informed on the latest controlled…
DEA Update on Scheduling Synthetic Cannabinoids in Schedule I
The DEA scheduling synthetic cannabinoids update highlights the placement of four novel compounds into Schedule I. These synthetic cannabinoids pose significant public health risks due to their high potency and unknown safety profiles. Clinicians should…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has issued the cumyl-pegaclone schedule i designation, reflecting its high abuse potential and lack of accepted medical use. This designation highlights regulatory efforts to control synthetic cannabinoids. Clinicians should be aware of the risks…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has issued temporary scheduling orders placing 2-fluorodeschloroketamine into Schedule I. These orders address emerging synthetic drugs and their regulatory challenges. Temporary scheduling orders are critical for managing novel substances with…
Schedules of Controlled Substances: Diphenidine Scheduling Update
The DEA has updated the diphenidine controlled substance scheduling to reflect its placement in Schedule I. This change addresses the drug's high abuse potential and lack of accepted medical use. Clinicians should stay informed about diphenidine…
Schedules of Controlled Substances Placement June 2026 Updates
This Policy Watch covers schedules of controlled substances placement June 2026 updates with 20 key regulatory items. The DEA's recent actions focus on synthetic cannabinoids and other substances. These changes affect clinical relevance and regulatory…
DEA Schedule I Synthetic Cannabinoids Control Update June 2026
This update covers the DEA Schedule I synthetic cannabinoids control update as of June 19, 2026. It details regulatory actions impacting synthetic cannabinoids and related substances. The report informs clinical practice and legal considerations.
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has enacted synthetic ketamine analog regulation by temporarily placing 2-fluorodeschloroketamine in Schedule I. This action highlights the challenges of controlling emerging designer drugs. Clinicians should monitor these regulatory changes…
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I
The DEA scheduling benzodiazepine analogs in Schedule I addresses the abuse potential of synthetic benzodiazepines. These substances pose significant clinical risks and regulatory challenges. Clinicians should be vigilant for exposure to these…
